Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Cencora

Cencora Stock: Is COR Outperforming the Health Care Sector?

Cencora has outperformed the Health Care sector over the past year, and analysts are highly optimistic about the stock’s prospects.

Cencora Stock: Analyst Estimates & Ratings

Cencora Stock: Analyst Estimates & Ratings

Cencora has outpaced the broader market over the past year, and Wall Street analysts maintain a highly optimistic outlook on the stock’s prospects.

Cencora Shows Rising Relative Price Performance; Still Shy Of Key Threshold

Cencora Shows Rising Relative Price Performance; Still Shy Of Key Threshold

Cencora shows improving price performance, earning an upgrade to its IBD Relative Strength Rating

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Cencora Says Famed GLP-1 Class Products Drive Growth, Boosts Profit Outlook

Cencora, Inc. (NYSE:COR) on Wednesday reported third-quarter 2025 sales increased 8.7% to $80.66 billion, beating the consensus of $80.354 billion.

Cencora Earns Relative Strength Rating Upgrade; Hits Key Threshold

A Relative Strength Rating upgrade for Cencora shows improving technical performance.

Investors Business Daily

Here's What to Expect From Cencora's Next Earnings Report

Cencora is scheduled to release its second-quarter results next month, with analysts projecting double-digit earnings growth.

Is Cencora Stock Outperforming the Dow?

Due to Cencora’s strong performance relative to the broader Dow over the past year, Wall Street analysts remain bullish about the stock’s prospects.

inkl

Read news from The Economist, FT, and more,
with one subscription

Do Wall Street Analysts Like Cencora Stock?

Do Wall Street Analysts Like Cencora Stock?

Cencora has significantly outperformed the broader market over the past year, and analysts remain strongly bullish on the stock’s prospects.

Earnings Preview: What To Expect From Cencora's Report

Earnings Preview: What To Expect From Cencora's Report

Cencora is scheduled to report its second-quarter results next month, with analysts projecting a single-digit earnings growth.

Top 3 S&P 500 Winners in a Losing Market

Top 3 S&P 500 Winners in a Losing Market

Despite a broad market correction in 2025, three S&P 500 stocks have defied the downturn, delivering standout performance and showcasing strong fundamentals.

This ‘Recession-Proof’ Stock Just Set New Highs and Is Flashing ‘Buy’ Signals

This ‘Recession-Proof’ Stock Just Set New Highs and Is Flashing ‘Buy’ Signals

Drug stocks like Cencora tend to be recession-proof, making today’s Chart of the Day especially relevant following a tariffs-driven selloff.

This Medical Services Stock Looks Relatively Healthy In A Sick Market

This Medical Services Stock Looks Relatively Healthy In A Sick Market

This medical supplies distributor raised its 2025 earnings outlook on Monday. Cencora stock is near a buy point of a newly formed base.

Investors Business Daily

Is Cencora Stock Outperforming the Nasdaq?

Is Cencora Stock Outperforming the Nasdaq?

As Cencora has outperformed relative to the broader Nasdaq Composite over the past year, Wall Street analysts maintain a bullish outlook on the stock’s prospects.

Stocks To Watch: Cencora Sees RS Rating Rise To 86

Stocks To Watch: Cencora Sees RS Rating Rise To 86

A Relative Strength Rating upgrade for Cencora shows improving technical performance.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Cencora Earns Composite Rating Upgrade

The IBD SmartSelect Composite Rating for Cencora rose from 94 to 96 Monday.

Investors Business Daily

IBD Rating Upgrades: Cencora Shows Improved Relative Price Strength

Cencora shows rising price performance, earning an upgrade to its IBD Relative Strength Rating

Cencora Stock Outlook: Is Wall Street Bullish or Bearish?

Despite Cencora's underperformance relative to the broader market over the past year, Wall Street analysts remain bullish on the stock's future.

Investors Business Daily

Stocks With Rising Relative Strength: Cencora

Cencora shows rising price performance, earning an upgrade to its IBD Relative Strength Rating

Get all your
news in one place.

100’s of premium titles.
One news app.

Cencora's Quarterly Earnings Preview: What You Need to Know

As Cencora prepares to release its first-quarter earnings this month, analysts project a modest single-digit bottom-line surge.

Is Cencora Stock Underperforming the S&P 500?

Cencora has trailed the S&P 500 index over the past year, but analysts remain highly bullish about the stock’s prospects.

Are Wall Street Analysts Predicting Cencora Stock Will Climb or Sink?

Cencora has underperformed the broader market over the past year, and Wall Street analysts appear moderately bullish about the stock’s future.

Investors Business Daily

Stock Market Today: Nasdaq, S&P 500 Add Gains But Small Caps Lag; Fed Makes Expected Rate Cut (Live Coverage)

Meta Platforms ushered a follow-on buy point near 564.

Cencora's Q4 2024 Earnings: What to Expect

Cencora is poised to announce its fourth-quarter results next month, and analysts predict a double-digit growth in the company’s bottom-line figure.

How Is Cencora's Stock Performance Compared to Other Healthcare Stocks?

Cencora has outperformed other healthcare stocks over the past year and analysts remain bullish about the stock’s prospects.

Is Wall Street Bullish or Bearish on Cencora Stock?

Cencora has outperformed the broader market over the past year, and Wall Street analysts remain bullish about the stock's prospects.

People

139,013 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

the Federal Reserve

Investor Business Daily

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

302,827 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play